





<b>INFORMATION DISCLOSURE STATEMENT</b> 37 CFR 1.56, 1.97, and 1.98  SHEET 1 OF 1				ATTORNEY DOCKET 25835-0014A		APPLICATION NO. 09/748,748	
				APPLICANT(S) Gerardo M. Castillo et al.			
				FILING DATE December 26, 2000		GROUP 1614	
<b>US PATENT DOCUMENTS</b>							
† EX'R INITIAL	REF. #	PATENT NUMBER	DATE (MO/YR)	NAME	CLASS/ SUBCLASS	FILING DATE (If appropriate)	
Z-F	1	5,767,126	06/1998	Marchbanks	514/297		
Z-F	2	6,297,281	10/2001	Chabrier de Lassauniere et al.	514/589	03/1999	
<b>FOREIGN PATENT DOCUMENTS</b>							
† EX'R INITIAL	* REF. #	PATENT NUMBER	DATE (MO/YR)	COUNTRY	TRANSLATION (YES/NO)		
Z-F	3	1-151514	06/1989	JP	Abstract		
Z-F	4	98/24646	06/1998	WO			
Z-F	5	98/09653	03/1998	WO	See ref. 2		
Z-F	6	98/34646	08/1998	WO			
<b>OTHER DOCUMENTS</b>							
† EX'R INITIAL	* REF. #	CITATION (Author, Article Title, Journal/Book Title, Date, Pertinent Pages, etc.)					
Z-F	7	C. Hertel et al, "Inhibition of the electrostatic interaction between $\beta$ -amyloid peptide and membranes prevents $\beta$ -amyloid-induced toxicity", <i>Proc. Nat'l Acad. Sci. USA</i> , 94(8), 9412-9416 (1997)					
Z-F	8	H. Niwano et al., "Inhibitory action of amyloid precursor protein against human Hageman factor (factor XII)", <i>J. Lab. Clin. Med.</i> , 125(2), 251-256 (1995)					
EXAMINER'S SIGNATURE 				DATE CONSIDERED 3/18/03			
† EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609. Line through citation if not in conformance and not considered. Include copy of this form in next communication to applicant.							
* If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identified in the statement and relied upon for an earlier filing date under 35 USC 120. 37 CFR 1.98(d).							

RECEIVED


MAR 12 2002

TECH CENTER 1600/2900

<b>INFORMATION DISCLOSURE STATEMENT</b> (37 CFR 1.56, 1.97, and 1.98)				Attorney Docket No.: 25835-0014A		Application Serial No.: 09/748,748	
				APPLICANT(S)		Confirmation No.:	
				Gerardo M. CASTILLO, et al.		4503	
				FILING DATE		GROUP	
				December 26, 2000		1614	
<b>US PATENT DOCUMENTS</b>							
† EXR INITIAL	* REF. #	PATENT NUMBER	DATE (MO/YR)	NAME	CLASS/ SUBCLASS	FILING DATE (If appropriate)	
2f	HH	5,747,517	05/05/1998	Panetta et al.	514/369		
2f	II	5,719,191	02/17/1998	Maclean et al	514/648		
2f	JJ	5,731,313	03/24/1998	Suarato et al.	514/255		
<b>FOREIGN PATENT DOCUMENTS</b>							
† EXR INITIAL	* REF. #	PATENT NUMBER	DATE (MO/YR)	COUNTRY		TRANSLATION (YES/NO)	
<b>OTHER DOCUMENTS</b>							
† EXR INITIAL	* REF. #	CITATION (Author, Article Title, Journal/Book Title, Date, Pertinent Pages, etc.)					
2f	KK	CASTILLO et al., "Sulfate Content and Specific Glycosaminoglycan Backbone of Perlecan Are Critical for Perlecan's Enhancement of Islet amyloid Polypeptide (Amylin) Fibril Formation," Diabetes, Vol. 47, pp.612-620, 1998.					
2f	LL	PUCHTLER et al., "On the Binding of Congo Red by Amyloid," ?? pp.355-364, 5 September 1961.					
EXAMINER'S SIGNATURE				DATE CONSIDERED			
				3/18/03			
† EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609. Line through citation if not in conformance and not considered. <i>Include copy of this form in next communication to applicant.</i>							
* If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identified in the statement and relied upon for an earlier filing date under 35 U.S.C. 120. 37 C.F.R. 1.98(d).							

JUL 25 2001


TECH CENTER 1600/2900

<b>INFORMATION DISCLOSURE STATEMENT</b> (37 CFR 1.56, 1.97, and 1.98)  SHEET 1 OF 5	ATTORNEY DOCKET 25835-0014A	APPLICATION NO. 09/748,748
	APPLICANT(S) Gerardo M. CASTILLO, et al.	Confirmation No.: 4503
	FILING DATE December 26, 2000	GROUP 1614

US PATENT DOCUMENTS						
† EX'R INITIAL	REF. #	PATENT NUMBER	DATE (MO/YR)	NAME	CLASS/ SUBCLASS	FILING DATE (If appropriate)

FOREIGN PATENT DOCUMENTS					
† EX'R INITIAL	* REF. #	PATENT NUMBER	DATE (MO/YR)	COUNTRY	TRANSLATION (YES/NO)

OTHER DOCUMENTS		
† EX'R INITIAL	* REF. #	CITATION (Author, Article Title, Journal/Book Title, Date, Pertinent Pages, etc.)
2-f	A	GLENNER et, al. "Alzheimer's Disease: Initial Report of the Purification and Characterization of a Novel Cerebrovascular Amyloid Protein," Biochemical and Biophysical Research Communications, Vol. 120, No.3, pp.885-890, May 16, 1984.
2-f	B	MASTERS et al., "Amyloid plaque core protein in Alzheimer disease and Down syndrome," Medical Sciences, Vol. 82, pp.4245-4249, June 1985.
2-f	C	WHO-IUIS Nomenclature Sub-Committee, "Nomenclature of amyloid and amyloidosis," Bulletin of the World Health Organization, Vol. 71, No.1. pp.105-108, 1993.
2-f	D	TANZI et al, "Protease inhibitor domain encoded by an amyloid protein precursor mRNA associated with Alzheimer's disease," Nature, Vol. 331, pp.528-532, 11 February, 1988
2-f	E	KITAGUCHI et al, "Novel precursor of Alzheimer's disease amyloid protein shows protease inhibitory activity," Nature, pp.530-532. Vol. 331, 11 February 1988
2-f	F	PONTE et al, "A new A4 amyloid mRNA contains a domain homologous to serine proteinase inhibitors," Nature, Vol. 331, pp.525-527. 11 February 1988.
2-f	G	MANDYBUR et al., "Cerebral Amyloid 'Angiopathy: The Vascular Pathology and Complications," Journal of Neuropathology and Experimental Neurology, Vol. 45, No.1, pp.79-90, January 1986.
2-f	H	PARDRIDGE et al., "Amyloid Angiopathy of Alzheimer's Disease: Amino Acid Composition and Partial Sequence of a 4,200-Dalton Peptide Isolated from Cortical Microvessels," Journal of Neurochemistry, Vol. 49, No.5, pp.1394-1401. 1987.

EXAMINER'S SIGNATURE 	DATE CONSIDERED 3/18/03
---	----------------------------



† EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609. Line through citation if not in conformance and not considered. Include copy of this form in next communication to applicant.

\* If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the

RECEIVED



JUL 25 2001



CENTER 1600/2900

PTO in a prior application that is identified in the statement and relied upon for an earlier filing date under 35 U.S.C. 120. 37 C.F.R. 1.98(d).							
<b>INFORMATION DISCLOSURE STATEMENT</b> (37 C.F.R. 1.56, 1.97, and 1.98)				Attorney Docket No.: 25835-0014A		Application Serial No.: 09/748,748	
 SHEET 2 OF 5				APPLICANT(S) Gerardo M. CASTILLO, et al.		Confirmation No.: 4503	
				FILING DATE December 26, 2000		GROUP 1614	
<b>US PATENT DOCUMENTS</b>							
† EXR INITIAL	REF. #	PATENT NUMBER	DATE (MO/YR)	NAME		CLASS/ SUBCLASS	FILING DATE (If appropriate)
<b>FOREIGN PATENT DOCUMENTS</b>							
† EXR INITIAL	* REF. #	PATENT NUMBER	DATE (MO/YR)	COUNTRY		TRANSLATION (YES/NO)	
<b>OTHER DOCUMENTS</b>							
† EXR INITIAL	* REF. #	CITATION (Author, Article Title, Journal/Book Title, Date, Pertinent Pages, etc.)					
2.f	I	PIKE et al., "In vitro aging of B-amyloid protein causes peptide aggregation and neurotoxicity," Brain Research, Vol. 563. pp.311-314. 1991.					
2.f	J	PIKE et al., "Structure-Activity Analyses of B-Amyloid Peptides: Contributions of the B25-35 Region to Aggregation and Neurotoxicity," Journal of Neurochemistry, Vol. 64, No.1, pp.253-265.					
2.f	K	HARRIGAN et al, "Beta Amyloid is Neurotoxic in Hippocampal Slice Cultures," Neurobiology of Aging, Vol. 16. No. 5, pp.779-789, 1995.					
2.f	L	GAMES et al., "Alzheimer-type neuropathology in transgenic mice overexpressing V717F B-amyloid precursor protein," Nature, Vol. 373, pp.523-527. 9 Feb. 1995.					
2.f	M	HSIAO et al., "Correlative Memory Deficits, AB Elevation, and Amyloid Plaques in Transgenic Mice," Science, Vol. 274, pp.99-102. 4 October 1996.					
2.f	N	FLOOD et al., "Amnestic effects in mice of four synthetic peptides homologous to amyloid B protein from patients with Alzheimer's disease," Proc. Natl. Acad. Sci. Vol. 88.pp.3363-3366, April 1991.					
2.f	O	FLOOD et al., "An amyloid B-protein fragment, AB[12-28], equipotently impairs post-training memory processing when injected into different limbic system structures," Brain Research, Vol. 663, pp.271-276. 1994.					
2.f	P	BROECKHOVEN et al, "Amyloid B Protein Precursor Gene and Hereditary Cerebral Hemorrhage with Amyloidosis (Dutch)," Science, Vol. 248. pp.1120-1121.					
EXAMINER'S SIGNATURE				DATE CONSIDERED			
				3/18/03			
† EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609. Line through citation if not in conformance and not considered. Include copy of this form in next communication to applicant.							
* If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identified in the statement and relied upon for an earlier filing date under 35 U.S.C. 120. 37 C.F.R. 1.98(d).							

JUL 25 2001

TECH CENTER 1600/2900

<b>INFORMATION DISCLOSURE STATEMENT</b> (37 CFR 1.56, 1.97, and 1.98)				Attorney Docket No.: 25835-0014A		Application Serial No.: 09/748,748	
				APPLICANT(S) Gerardo M. CASTILLO, et al.		Confirmation No.: 4503	
				FILING DATE December 26, 2000		GROUP 1614	
<b>US PATENT DOCUMENTS</b>							
† EX'R INITIAL	REF. #	PATENT NUMBER	DATE (MO/YR)	NAME		CLASS/ SUBCLASS	FILING DATE (If appropriate)
<b>FOREIGN PATENT DOCUMENTS</b>							
† EX'R INITIAL	REF. #	PATENT NUMBER	DATE (MO/YR)	COUNTRY		TRANSLATION (YES/NO)	
<b>OTHER DOCUMENTS</b>							
† EX'R INITIAL	REF. #	CITATION (Author, Article Title, Journal/Book Title, Date, Pertinent Pages, etc.)					
2.f	Q	MURRELL et al., "A Mutation in the Amyloid Precursor Protein Associated with Hereditary Alzheimer's Disease," Science, Vol. 254, pp.97-99, 4, October, 1991.					
2.f	R	HAASS et al., "The Swedish mutation causes early-onset Alzheimer's disease by B-secretase cleavage within the secretory pathway," Nature Medicine, Vol. 1, No.12. pp.1291-1296. December 1995.					
2.f	S	POLLANEN et al., "Pathology and Biology of the Lewy Body," Journal of Neuropathology and Experimental Neurology, Vol. 52, No.3 pp.183-191, May 1993.					
2.f	T	GRAZIA et al., "a-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies," Proc. Natl. Acad. Sci. Vol. 95, pp.6469-6473, May 1998.					
2.f	U	ARAI et al., "Argyrophilic glial inclusions in the midbrain of patients with Parkinson's disease and diffuse Lewy body disease are immunopositive for NACP/a-synuclein," Neuroscience Letters, Vol. 259. pp.83-86, 1999.					
2.f	V	UEDA et al., "Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer's disease," Proc. Natl. Acad. Sci. Vol. 90. pp.11282-11286. December 1993.					
2.f	W	POLYMERPOULOS et al., "Mutation in the a-sSynuclein Gene Identified in Families with Parkinson's Disease," Science, Vol. 276. pp.2045-2047. 27 June 1997.					
2.f	X	REJKO et al., "Ala30Pro mutation in the gene encoding a-synuclein in Parkinson's disease," Nature Genetics, Vol. 18, February 1998.					
2.f	Y	CONWAY et al., "Accelerated in Vitro fibril formation by a mutant a-synuclein linked to early-onset Parkinson disease," Nature medicine, Vol. 4, No.11, November. 1998.					
EXAMINER'S SIGNATURE 				DATE CONSIDERED 3/18/03			
† EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609. Line through citation if not in conformance and not considered. Include copy of this form in next communication to applicant.							
* If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identified in the statement and relied upon for an earlier filing date under 35 U.S.C. 120. 37 C.F.R. 1.98(d).							

INFORMATION DISCLOSURE STATEMENT				Attorney Docket No.: 25835-0014A		Application Serial No.: 09/748,748	
<div style="display: flex; align-items: center; justify-content: center;"> <div style="text-align: center;">  <p>SHEET 4 OF 5</p> </div> </div>				APPLICANT(S)		Confirmation No.:	
				Gerardo M. CASTILLO, et al.		4503	
				FILING DATE		GROUP	
		December 26, 2000		1614			
<b>US PATENT DOCUMENTS</b>							
† EXR INITIAL	REF. #	PATENT NUMBER	DATE (MO/YR)	NAME		CLASS/ SUBCLASS	FILING DATE (If appropriate)
<b>FOREIGN PATENT DOCUMENTS</b>							
† EXR INITIAL	REF. #	PATENT NUMBER	DATE (MO/YR)	COUNTRY		TRANSLATION (YES/NO)	
<b>OTHER DOCUMENTS</b>							
† EXR INITIAL	REF. #	CITATION (Author, Article Title, Journal/Book Title, Date, Pertinent Pages, etc.)					
2.f	Z	HASHIMOTO et al., "Human recombinant NACP/a-synuclein is aggregated and fibrillated in vitro: Relevance for Lewy body disease," Brain Research, Vol. 799, pp.301-306, 1998.					
2.f	AA	NARHI et al., "Both Familial Parkinson's Disease Mutations Accelerate a-Synuclein Aggregation," The Journal of Biological Chemistry, Vol. 274. No.14, pp.9843-9846, 2 April 1999.					
2.f	BB	WOOD et al., "a-Synuclein Fibrillogenesis Is Nucleation-dependent," The Journal of Biological Chemistry, Vol. 274. No. 28, pp.19509-19512, 9 July 1999.					
2.f	CC	NAIKI et al., "Kinetic Analysis of Amyloid Fibril Polymerization In vitro," Laboratory Investigation, Vol. 65, No.1, pp.104-110. 1991.					
2.f	DD	LEVINE et al., "Thioflavine T interaction with synthetic Alzheimer's disease B-amyloid peptides: Detection of amyloid aggregation in solution," Protein Science, Vol. 2, pp.404-410, 1993.					
2.f	EE	NAIKI et al., "First-Order Kinetic Model of Alzheimer's B-amyloid Fibril Extension In Vitro," Laboratory Investigation, Vol. 74, No. 2, pp.374-383. 1996.					
2.f	FF	KLUNK et al., "Quantifying Amyloid B-Peptide (AB) Aggregation Using the Congo Red-AB (CR-AB) Spectrophotometric Assay, Analytical Biochemistry, vol. 266, pp.66-76. 1999.					
2.f	GG	COOPER et al., "Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients," Medical Sciences, Vol. 84, pp.8628-8632, Dec. 1987.					
EXAMINER'S SIGNATURE				DATE CONSIDERED			
				3/18/03			
† EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609. Line through citation if not in conformance and not considered. Include copy of this form in next communication to applicant.							
* If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identified in the statement and relied upon for an earlier filing date under 35 U.S.C. 120. 37 C.F.R. 1.98(d).							